GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,306.00p
   
  • Change Today:
      6.00p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,300.00
  • Currency: UK Pounds
  • Shares Issued: 4,145.10m
  • Volume: 3,636,262
  • Market Cap: £54,135m
  • RiskGrade: 129
  • Beta: 0.56

News Wires

FDA Approves Promacta(R) (Eltrombopag), the Firs... 20-Nov-2008 PR Newswire
Study Found That Long Term Use of Advair Diskus(... 29-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire Genelabs Technologies... 29-Oct-2008 PR Newswire
New Research Shows Many Patients with Persistent... 28-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire the Leading Dry Mouth... 21-Oct-2008 PR Newswire
GSK Notice of Third Quarter 2008 Results Announc... 20-Oct-2008 PR Newswire
LF Elimination Program Treats Over Half Billion ... 07-Oct-2008 PR Newswire
alli(TM) Partners with Breast Cancer Network of ... 22-Sep-2008 PR Newswire
MultiVu Video Feed: NEW BRAIN IMAGING SHOWS THE ... 18-Sep-2008 PR Newswire
GSK and XenoPort Announce Submission of New Drug... 16-Sep-2008 PR Newswire
A New Interactive Consumer Experience Highlighti... 28-Sep-2007 PR Newswire
AUDIO from Medialink and GlaxoSmithKline: A New ... 28-Sep-2007 PR Newswire
GSK Receives Decision From FDA on Advair(R) 500/... 08-Aug-2007 PR Newswire
GlaxoSmithKline Receives New HHS Order for H5N1 ... 03-Aug-2007 PR Newswire
FDA Issues Second Approvable Letter for Trexima(... 02-Aug-2007 PR Newswire
GlaxoSmithKline Presents Avandia Data To FDA 30-Jul-2007 PR Newswire
FDA Advisory Panel Votes 22 to 1 for Avandia(R) ... 30-Jul-2007 PR Newswire
ChemoCentryx Achieves $5 Million Milestone from ... 24-Jul-2007 PR Newswire
GSK's Cervical Cancer Candidate Vaccine Cervarix... 18-Jul-2007 PR Newswire
Pharmacopeia Advances First Therapeutic Program ... 17-Jul-2007 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,306.00p
Change Today 6.00p
% Change 0.46 %
52 Week High 1,812.50
52 Week Low 1,300.00
Volume 3,636,262
Shares Issued 4,145.10m
Market Cap £54,135m
Beta 0.56
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average48.16% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average
18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average18.37% above the sector average
Income
47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average47.15% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average5.4% below the market average
23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average23.53% above the sector average

What The Brokers Say

Strong Buy 7
Buy 4
Neutral 11
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 15-Nov-24 15-Aug-24
Paid 09-Jan-25 10-Oct-24
Amount 15.00p 15.00p

Trades for 21-Nov-2024

Time Volume / Share Price
15:44 360 @ 1,306.00p
15:44 761 @ 1,306.20p
15:44 175 @ 1,306.19p
15:43 7 @ 1,306.50p
15:43 4 @ 1,306.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page